戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (left1)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              IgG4-RD can affect any organ and has a heterogeneous pre
2                                              IgG4-RD is a multiorgan autoimmune disorder characterize
3                                              IgG4-RD is characterized by a lymphoplasmacytic infiltra
4                                              IgG4-RD lesions are infiltrated by T helper cells, which
5                                              IgG4-RD patients had more frequent recurrent disease tha
6                                              IgG4-RD should be added to the causes of cutaneous pseud
7                                              IgG4-RD should be considered in patients with unusual ne
8                                              IgG4-RD was confirmed by very high IgG4+ to IgG+ plasma
9                                              IgG4-RD was more frequent in patients with bilateral dis
10 38(hi) plasmablasts are a hallmark of active IgG4-RD.
11  peripheral blood of 84 patients with active IgG4-RD were analyzed by using flow cytometry.
12 G4(+), are increased in patients with active IgG4-RD.
13  in tissue are hallmarks of the disease, and IgG4-RD is associated with increased IgG4 serum levels.
14 s emerging roles in immune dysregulation and IgG4-RD, including clinical manifestations and treatment
15 ncreas is the organ that is most affected by IgG4-RD, which can simulate a tumor.
16 xteen patients with histologically confirmed IgG4-RD, 11 patients with sarcoidosis, and 30 healthy su
17 cular immunoglobulin (Ig)G4-related disease (IgG4-RD) and marginal zone lymphomas (MZLs).
18 he differences between IgG4-related disease (IgG4-RD) and non-IgG4-RD.
19           Immunoglobulin G4-related disease (IgG4-RD) comprises a group of immune-mediated diseases t
20                        IgG4-related disease (IgG4-RD) has complex clinical manifestations ranging fro
21                        IgG4-related disease (IgG4-RD) has only existed as a unique disease entity sin
22                        IgG4-related disease (IgG4-RD) is a fibroinflammatory condition involving loss
23                        IgG4-related disease (IgG4-RD) is a fibroinflammatory disorder that can affect
24                        IgG4-related disease (IgG4-RD) is a poorly understood, multiorgan, chronic inf
25                        IgG4-related disease (IgG4-RD) is a systemic fibroinflammatory condition affec
26                        IgG4-related disease (IgG4-RD) is a systemic immune-mediated fibroinflammatory
27    Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) is an immune-mediated condition that can affect
28                        IgG4-related disease (IgG4-RD) is characterized by a lymphoplasmacytic infiltr
29                        IgG4-related disease (IgG4-RD) is characterized by an inflammatory reaction ri
30    Immunoglobulin G4 (IgG4)-related disease (IgG4-RD) of the biliary tree and pancreas is difficult t
31  disease entity called IgG4-related disease (IgG4-RD), a systemic fibroinflammatory disorder characte
32 seases, 4 had confirmed IG4-related disease (IgG4-RD), and 5 developed B-cell malignancies: lymphoma
33                     In IgG4-related disease (IgG4-RD), skin involvement is rare and associated especi
34 rring in patients with IgG4-related disease (IgG4-RD).
35 nderlies autoimmunity/inflammatory diseases, IgG4-RD, and B-cell malignancies, the onset of which may
36 been proposed that allergic mechanisms drive IgG4-RD.
37 ere, we identified gene variants in familial IgG4-RD and determined their functional consequences.
38 s IOI are highly recommended to evaluate for IgG4-RD.
39 sease model that is not only instructive for IgG4-RD but also for atopic diseases and autoimmune dise
40 pathway contributing to T cell activation in IgG4-RD.
41   The role of B cells and IgG4 antibodies in IgG4-RD pathogenesis is not well defined.
42 h2 and regulatory T-cell (Treg) cytokines in IgG4-RD and in IgG4-associated MZL and IgG4-negative MZL
43        Rituximab-induced B cell depletion in IgG4-RD leads to rapid clinical and histological improve
44 ocrine gland antigens have been described in IgG4-RD, whether they are members of the IgG4 subclass i
45                  Reduced USP25 expression in IgG4-RD leads to increased SMAD3 activation, which contr
46 = 12.11; P = 0.008) were frequently found in IgG4-RD patients.
47 vides insights into pathogenic mechanisms in IgG4-RD and, potentially, other autoimmune diseases.
48 autoreactive IgG4 antibodies are observed in IgG4-RD, there is no evidence that they are directly pat
49 uld be considered as a therapeutic option in IgG4-RD.
50        Head and brain involvement is rare in IgG4-RD, and brain parenchyma involvement has never been
51 hat Th2 responses that have been reported in IgG4-RD may result from concomitant atopic manifestation
52 bution of atopy to enhanced Th2 responses in IgG4-RD.
53 targets that promote pathogenic responses in IgG4-RD.
54 c marker and potential therapeutic target in IgG4-RD.
55         A man in his mid-50s with multiorgan IgG4-RD developed progressive spastic hemiparesis and de
56 tween IgG4-related disease (IgG4-RD) and non-IgG4-RD.
57 n 23.8% of IgG4-RD patients and 41.7% of non-IgG4-RD patients.
58 had more frequent recurrent disease than non-IgG4-RD patients.
59                                       Ocular IgG4-RD and IgG4-associated MZL exhibited significantly
60                                Nearly 50% of IgG4-RD patients were previously diagnosed with biopsy-p
61      Complete remission occurred in 23.8% of IgG4-RD patients and 41.7% of non-IgG4-RD patients.
62 e authors investigated a familial cluster of IgG4-RD that consisted of an affected father and two dau
63             The recognition and diagnosis of IgG4-RD are crucial because the disease responds favorab
64                             The diagnosis of IgG4-RD unifies many eponymous fibroinflammatory conditi
65  sensitive nor specific for the diagnosis of IgG4-RD.
66 eria have been proposed for the diagnosis of IgG4-RD: clinical, laboratory, and histological.
67 ineation, early diagnosis, and monitoring of IgG4-RD of the biliary tree and pancreas.
68 gic mechanism underlying the pathogenesis of IgG4-RD.
69 made in understanding the pathophysiology of IgG4-RD.
70 y both the robust clinical responsiveness of IgG4-RD to B cell depletion and by the identification of
71 bset of ocular MZLs arises in the setting of IgG4-RD.
72 n understanding the genetic underpinnings of IgG4-RD, highlighting the significance of germline gene
73  peripheral blood mononuclear cells (PBMCs), IgG4-RD cell lines and Usp25 knockout mice, we show that
74           We report 2 cases of isolated skin IgG4-RD successfully treated with thalidomide and invest
75 discusses the IgG4-related disease spectrum (IgG4-RD), the autoimmune polyglandular syndromes (APS),
76                   It has been suggested that IgG4-RD is characterized by allergic manifestations and
77 of a quantitative disease activity tool (the IgG4-RD Responder Index) and the validation of classific
78        The contribution of autoantibodies to IgG4-RD remains unclear.
79 ammatory pathways that are characteristic to IgG4-RD.
80 d IgE, suggesting that processes inherent to IgG4-RD itself rather than atopy per se contribute to th
81 milar to those for patients with unexplained IgG4-RD.
82                      In this study, by using IgG4-RD patient peripheral blood mononuclear cells (PBMC
83  plasmablast-derived mAb from a patient with IgG4-RD.
84 monstrate that the majority of patients with IgG4-RD are nonatopic.
85 ease, and a high proportion of patients with IgG4-RD are reported to have longstanding allergies, per
86                    Plasma from patients with IgG4-RD exhibited elevated levels of reactivity against
87                   We evaluated patients with IgG4-RD for activated B cells in both disease lesions an
88                    A subset of patients with IgG4-RD have anti-IL-1RA autoantibodies, which promote p
89 arameters in a large cohort of patients with IgG4-RD in whom a wide range of organs were affected by
90                   Furthermore, patients with IgG4-RD, but not patients with sarcoidosis, had increase
91 phocyte signature" observed in patients with IgG4-RD, could support diagnosis and treatment monitorin
92 quent atopic manifestations in patients with IgG4-RD, including the affected family members in the pr
93 lood IgG4(+) memory B cells in patients with IgG4-RD.
94 ns has ever been undertaken in patients with IgG4-RD.
95  dysregulated IgG4 response in patients with IgG4-RD.
96 ected in lesional tissues from patients with IgG4-RD.
97 common disease pathogenesis in patients with IgG4-RD.
98 ablast antibody repertoires in patients with IgG4-RD.